Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Cornell University
Tech Transfer Roundup: Mydecine, Johns Hopkins Pair Up To Study Psychedelics
BioMed X teams with J&J on inflammation, drug delivery research. Stem cell firm Calidi inks licensing deals with U. of Chicago, City of Hope and Northwestern. MD Anderson teams with Blueprint and Hummingbird.
Tech Transfer Roundup: Sanofi Gets IP For Multiple Myeloma From Memorial Sloan Kettering
The intellectual property, also held by Eureka, may offer a new pathway for treating relapsed MM patients. Sorrento inks cancer partnerships with Karolinska Institutet and Mayo Clinic.
Tech Transfer Roundup: J&J Houses JPOD Incubator At University Of Pennsylvania
Pascal and Oblato separately license therapeutic candidates for glioblastoma multiforme, while Cabaletta emerges from UPenn with novel program for CAAR-T therapies in B-cell mediated autoimmune disease.
Stem Cell System Shows How Gene Silencing Causes Fragile X Syndrome
Using stem cells, researchers have shown that the gene mutation that causes fragile X leads to gene silencing through the binding of a small repeat mRNA transcript to the gene itself. They further show that a small molecule can disrupt this RNA-DNA duplex, preventing the disease from occurring and suggesting a potential prenatal therapy.
- Academic and Research Institutions
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.